PharmaEssentia Corporation (LUX: 261280523)

Market Cap	5.54B
Revenue (ttm)	234.87M
Net Income (ttm)	52.11M
Shares Out	n/a
EPS (ttm)	0.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	19.10
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2024

About PharmaEssentia

PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutro...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1990
• Employees: 131
• Stock Exchange: Luxembourg Stock Exchange
• Ticker Symbol: 261280523

Financial Performance

In 2023, PharmaEssentia's revenue was 5.11 billion, an increase of 77.15% compared to the previous year's 2.88 billion. Losses were -623.84 million, -54.62% less than in 2022.

Financial numbers in TWD